|1.||Emerich, D F: 6 articles (05/2003 - 01/2000)|
|2.||Bartus, R T: 6 articles (02/2001 - 01/2000)|
|3.||Snodgrass, P: 5 articles (02/2001 - 01/2000)|
|4.||Marsh, J: 4 articles (02/2001 - 06/2000)|
|5.||Dean, R L: 4 articles (02/2001 - 01/2000)|
|6.||Lafreniere, D: 3 articles (02/2001 - 10/2000)|
|7.||Pink, M: 3 articles (02/2001 - 10/2000)|
|8.||Agostino, M: 3 articles (02/2001 - 06/2000)|
|9.||Jakacki, Regina: 2 articles (11/2005 - 09/2005)|
|10.||Allen, Jeffrey: 2 articles (11/2005 - 09/2005)|
05/15/2003 - "Although initially developed to increase the permeability of the vasculature feeding glioma, recent studies have demonstrated that Cereport also increases the delivery of pharmacological agents across the normal (i.e. "
10/01/1996 - "The effect and mechanism of the blood-brain barrier-permeabilizing agent, RMP-7, was investigated in a series of studies employing a rat RG2 glioma model. "
01/01/2000 - "The present experiments tested the hypothesis that the ability of Cereport to increase the permeability of infiltrating glioma colonies increases as the glioma colonies develop, in situ. "
11/01/1999 - "Intracarotid rrIFN-gamma treatment can increase survival in rat glioma models through a mechanism in which antigen presentation is enhanced, and such effects are not always further increased by combination with RMP-7."
06/01/1999 - "A series of experiments was performed in an RG2 rodent model of glioma to evaluate and refine intravenous (i.v.) parameters to optimize Cereport's clinical utility. "
|2.||Brain Neoplasms (Brain Tumor)
10/01/1996 - "The combined results from these studies therefore offer new insight into the characteristics of the vascular barriers in normal and tumor brain tissue and further elucidate the novel permeability effects of RMP-7. "
06/01/2000 - "These data offer fundamental information regarding the effects of Cereport on delivery of chemotherapeutic agents to brain tumors and provide new insight into receptor-mediated permeability of the blood-brain tumor barrier."
01/01/1999 - "These findings indicate that intracarotid delivery of RMP-7 can augment the selective delivery of virus vectors to brain tumors in an experimental rat model, with the potential for application to human brain tumors."
01/01/1999 - "Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7."
04/01/1997 - "Intracarotid infusion of RMP-7 is a novel technique for selective delivery of antitumor compounds into brain tumors."
07/01/2000 - "administration of Cereport can not only increase tumor uptake of BPA, but also enhance the efficacy of BNCT."
01/01/1999 - "This study was initiated to determine whether RMP-7 would open the blood-tumor barrier to virus vectors encoding tumor-killing genes in an experimental model. "
02/01/2002 - "Thus the combination of ICG and RMP-7 administered preoperatively may provide visual enhancement of an infiltrating tumor and its margins to help facilitate a radical tumor removal."
02/01/2001 - "At the physical level we demonstrate that Cereport modifies the tumor vasculature in several important ways, including transient 1) reductions in interstitial fluid pressure within the tumor, 2) increases in pore size of the vasculature, and 3) increases in total vascular surface area. "
10/01/2000 - "Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain."
08/01/2001 - "These data indicated that Cereport infused with ACV enhances both the penetration and efficacy of this drug in the treatment of an experimental HSV-1 infection of the rat brain."
08/01/2001 - "In these studies we utilized a synthetic bradykinin analog, Cereport (RMP-7), in conjunction with ACV to treat HSV infection of the brain in a rat model. "
|5.||Glioblastoma (Glioblastoma Multiforme)
04/01/2003 - "Adults with recurrent glioblastoma multiforme or anaplastic glioma were randomized in a 1:1 ratio to receive carboplatin and either RMP-7 or placebo. "
05/01/2002 - "In 43 chemotherapy naïve patients, 26 glioblastoma multiforme (GBM) + 17 anaplastic astrocytoma (AA), median age 45 years, MRI responses to intravenous cereport and carboplatin were assessed at baseline, then at 2 monthly intervals. "
10/01/1998 - "In this dose ranging study, 14 patients with progressing malignant glioma (9 glioblastoma multiforme, 4 anaplastic astrocytoma, 1 anaplastic oligodendroglioma; age range 31-68 years, baseline Karnofsky range 60-90%, 5 having had prior chemotherapy) were treated with intravenous RMP-7 and carboplatin to assess the safety, tolerability, and side-effect profile of increasing doses of this combination. "
|7.||Nerve Growth Factor (NGF)
|8.||Indocyanine Green (Cardio-Green)
|10.||Bradykinin B2 Receptor
|1.||Boron Neutron Capture Therapy
|2.||Drug Therapy (Chemotherapy)